The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Finding a link for the proposed beneficial effects of omega-3 on Alzheimer’s disease

    I usually shy away from animal data. After all, there’s a long road between the lab and the medicine chest.

    However, in light of my nominee for CAM of the year (see 12/31/07 posts) the results published by researchers from California and Osaka are interesting.

    Here are the highlights from the NewsWise article.

    • Omega-3 fatty acid docosahexaenoic acid (DHA) found in fish oil increased the production of LR11 (lipoprotein receptor 11) in rat and mice studies.
    • LR11 is a protein found at reduced levels in patients with Alzheimer’s.
    • LR11 can destroy the protein that forms the “plaques” (see the black lines in the photo) associated with the disease.
    • Even at low doses, DHA increased LR11 levels in rat nerve fibers.
    • Dietary DHA increased LR11 in brains of rats or older mice that had been bred to develop Alzheimer’s disease.
    • The benefits of DHA were not limited to nonhuman animal cells. There was a direct impact on human nerves in cell cultures as well.

    The bottom line?
    Based on these positive laboratory results, the National Institutes of Health is conducting a large-scale study of DHA in patients with established Alzheimer’s disease. Lead author, Dr. Greg Cole believes, “it may be too late in the disease to help these patents, but it’s a first step that will eventually lead to research in earlier stages of the disease.”

    In fact, an earlier study also concluded that the potential for omega-3 might be in people with mild dementia.

    More on LR11 here.

    12/27/07 14:06 JR

    Leave a Comment

    You must be logged in to post a comment.